Europe Sexually Transmitted Diseases (STD) Testing Market By Disease Type (Chlamydia, Herpes simplex, Gonorrhea, Syphilis, Human papillomavirus (HPV), and Other Disease), By the Location of Testing (Laboratory Testing and Point of care (POC) Testing), By

Europe Sexually Transmitted Diseases (STD) Testing Market By Disease Type (Chlamydia, Herpes simplex, Gonorrhea, Syphilis, Human papillomavirus (HPV), and Other Disease), By the Location of Testing (Laboratory Testing and Point of care (POC) Testing), By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

The Europe Sexually Transmitted Diseases (STD) Testing Market would witness market growth of 4.0% CAGR during the forecast period (2021-2027).

The growth of the sexually transmitted diseases (STD) testing market are increased public awareness and patient education. Furthermore, rising number of education programmes, and an increase in government initiatives would fuel the demand for STD testing. In the last decade, the frequency and incidence of STDs have increased dramatically. Several countries around the world are highly focusing on implementing nationwide screening programmes to boost STD diagnosis coverage. Additionally, reimbursement policies for STD services have been beneficial for patients, which is further contributing considerably to the growth of STD testing market.

HIV/AIDS prevention, treatment, and care are gaining more significance in Europe over the last few decades. In the WHO European Region, where no country has been spared, more than two million individuals are infected with the disease. Despite the fact that this number is low when compared to the worst-affected region, it marks an unprecedented spike in new cases. The rapid spread of HIV in Eastern Europe, in particular, is one of the region's most pressing public health issues. In addition, Europe is likely to provide the most instructive combination of both actual success stories (from the region's western and central parts) and cautionary tales of missed possibilities (from its eastern part).

The Germany market dominated the Europe Sexually Transmitted Diseases (STD) Testing Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $8.07 billion by 2027. The UK market is estimated to witness a CAGR of 3.3% during (2021 - 2027). Additionally, The France market would experience a CAGR of 4.8% during (2021 - 2027).

Based on Disease Type, the market is segmented into Chlamydia, Herpes simplex, Gonorrhea, Syphilis, Human papillomavirus (HPV), and Other Disease. Based on the Location of Testing, the market is segmented into Laboratory Testing and Point of care (POC) Testing. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., DiaSorin Molecular LLC, Danaher Corporation, Bio-Rad Laboratories, Inc., and OraSure Technologies, Inc.

Scope of the Study

Market Segments covered in the Report:

By Disease Type

• Chlamydia
• Herpes simplex
• Gonorrhea
• Syphilis
• Human papillomavirus (HPV)
• Other Disease

By Location of Testing

• Laboratory Testing
• Point of care (POC) Testing

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Companies Profiled

• BioMérieux S.A.
• Abbott Laboratories
• Becton, Dickinson and Company
• Hologic, Inc.
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• DiaSorin Molecular LLC
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• OraSure Technologies, Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free